Con el doctor Miguel Albanese, presidente de PANLAR, exploramos lo que Barranquilla tiene para sorprendernos. Reumatología a la calle es el legado que se busca dejar como muestra de la integración con la población.
{"title":"Reumatología a la calle, la gran apuesta de PANLAR 2024","authors":"E. Fajardo","doi":"10.46856/grp.233.e187","DOIUrl":"https://doi.org/10.46856/grp.233.e187","url":null,"abstract":"Con el doctor Miguel Albanese, presidente de PANLAR, exploramos lo que Barranquilla tiene para sorprendernos. Reumatología a la calle es el legado que se busca dejar como muestra de la integración con la población.","PeriodicalId":187344,"journal":{"name":"Global Rheumatology","volume":"11 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140738710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Manuel Ugarte, president of the Scientific Committee of the PANLAR 2024 Congress, discusses the main topics of the event, as well as the integration with other specialties and patient groups. A program for all tastes, interests, and audiences.
{"title":"PANLAR 2024, Barranquilla brings an academic program for all interests","authors":"Estefanía Fajardo","doi":"10.46856/grp.233.et188","DOIUrl":"https://doi.org/10.46856/grp.233.et188","url":null,"abstract":"Manuel Ugarte, president of the Scientific Committee of the PANLAR 2024 Congress, discusses the main topics of the event, as well as the integration with other specialties and patient groups. A program for all tastes, interests, and audiences.","PeriodicalId":187344,"journal":{"name":"Global Rheumatology","volume":"9 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140738523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Manuel Ugarte, presidente do Comitê Científico do Congresso PANLAR 2024, fala sobre os principais temas do evento, bem como sobre a integração com outras especialidades e grupos de pacientes. Um programa para todos os gostos, interesses e públicos.
{"title":"PANLAR 2024, Barranquilla traz um programa acadêmico para todos os interesses","authors":"Estefanía Fajardo","doi":"10.46856/grp.233.ept188","DOIUrl":"https://doi.org/10.46856/grp.233.ept188","url":null,"abstract":"Manuel Ugarte, presidente do Comitê Científico do Congresso PANLAR 2024, fala sobre os principais temas do evento, bem como sobre a integração com outras especialidades e grupos de pacientes. Um programa para todos os gostos, interesses e públicos.","PeriodicalId":187344,"journal":{"name":"Global Rheumatology","volume":"28 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140740049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This year, in addition to the VII Pan American Congress of Patients with Rheumatic Diseases, patients will have an active role in the development of PANLAR 2024 Congress within the scientific program and community activities.
{"title":"Patient-Centered Medicine Takes Center Stage at PANLAR 2024","authors":"Estefanía Fajardo","doi":"10.46856/grp.27.et184","DOIUrl":"https://doi.org/10.46856/grp.27.et184","url":null,"abstract":"This year, in addition to the VII Pan American Congress of Patients with Rheumatic Diseases, patients will have an active role in the development of PANLAR 2024 Congress within the scientific program and community activities.","PeriodicalId":187344,"journal":{"name":"Global Rheumatology","volume":"33 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140797146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Após 15 anos, a PANLAR atualizará as diretrizes para Artrite Reumatoide (AR) visando abordar as especificidades dos sistemas de saúde e o manejo da doença nos países membros. Além disso, espera que sejam amigáveis para diversos públicos estratégicos.
{"title":"Diretrizes de Prática Clínica para Artrite Reumatoide da PANLAR: Uma Abordagem Abrangente para Todos","authors":"Estefanía Fajardo","doi":"10.46856/grp.27.ept185","DOIUrl":"https://doi.org/10.46856/grp.27.ept185","url":null,"abstract":"Após 15 anos, a PANLAR atualizará as diretrizes para Artrite Reumatoide (AR) visando abordar as especificidades dos sistemas de saúde e o manejo da doença nos países membros. Além disso, espera que sejam amigáveis para diversos públicos estratégicos.","PeriodicalId":187344,"journal":{"name":"Global Rheumatology","volume":"124 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140790298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Este año, adicional al VII Congreso Panamericano de Pacientes con Enfermedades Reumáticas, contarán con participación activa en el desarrollo del Congreso PANLAR 2024 en el marco del programa científico y actividades con la comunidad.
{"title":"Medicina centrada en los pacientes, un rol protagónico en PANLAR 2024","authors":"E. Fajardo","doi":"10.46856/grp.27.e184","DOIUrl":"https://doi.org/10.46856/grp.27.e184","url":null,"abstract":"Este año, adicional al VII Congreso Panamericano de Pacientes con Enfermedades Reumáticas, contarán con participación activa en el desarrollo del Congreso PANLAR 2024 en el marco del programa científico y actividades con la comunidad.","PeriodicalId":187344,"journal":{"name":"Global Rheumatology","volume":"413 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140757626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Framed within the scientific dissemination in Rheumatology, GR will have a special participation in PANLAR 2024 with a narrative workshop. The commitment of the journal to maintain and strengthen standards of quality and excellence in the dissemination of scientific knowledge remains.
{"title":"Global Rheumatology becomes the official journal of PANLAR","authors":"Estefanía Fajardo","doi":"10.46856/grp.27.et186","DOIUrl":"https://doi.org/10.46856/grp.27.et186","url":null,"abstract":"Framed within the scientific dissemination in Rheumatology, GR will have a special participation in PANLAR 2024 with a narrative workshop. The commitment of the journal to maintain and strengthen standards of quality and excellence in the dissemination of scientific knowledge remains.","PeriodicalId":187344,"journal":{"name":"Global Rheumatology","volume":"371 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140773377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Enmarcada en la difusión científica en Reumatología, GR tendrá participación especial en PANLAR 2024 con un taller de narrativas. El compromiso de la revista con mantener y fortalecer los estándares de calidad y excelencia en la difusión del conocimiento científico se mantiene.
{"title":"Global Rheumatology se convierte en la revista oficial de PANLAR","authors":"E. Fajardo","doi":"10.46856/grp.27.e186","DOIUrl":"https://doi.org/10.46856/grp.27.e186","url":null,"abstract":"Enmarcada en la difusión científica en Reumatología, GR tendrá participación especial en PANLAR 2024 con un taller de narrativas. El compromiso de la revista con mantener y fortalecer los estándares de calidad y excelencia en la difusión del conocimiento científico se mantiene.","PeriodicalId":187344,"journal":{"name":"Global Rheumatology","volume":"56 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140775060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
After 15 years, PANLAR will update the Rheumatoid Arthritis (RA) guidelines, aiming to address the specificities of healthcare systems and disease management in its member countries. Additionally, it hopes to make them user-friendly for diverse strategic audiences.
{"title":"Clinical Practice Guidelines for Rheumatoid Arthritis PANLAR: A Comprehensive Approach for All","authors":"Estefanía Fajardo","doi":"10.46856/grp.27.et185","DOIUrl":"https://doi.org/10.46856/grp.27.et185","url":null,"abstract":"After 15 years, PANLAR will update the Rheumatoid Arthritis (RA) guidelines, aiming to address the specificities of healthcare systems and disease management in its member countries. Additionally, it hopes to make them user-friendly for diverse strategic audiences.","PeriodicalId":187344,"journal":{"name":"Global Rheumatology","volume":"8 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140765413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Certolizumab pegol (CTZ) is a tumor necrosis factor-alpha (TNF-α) inhibitor biological agent that has demonstrated efficacy in controlling rheumatoid arthritis (RA). Identifying predictive factors for treatment success and assessing its effectiveness in a real-world clinical setting are crucial for decision-making. Objective: To evaluate the response to CTZ in patients with RA in a real-world cohort, measuring the reduction in DAS 28, HAQ, frequency of remission, and low disease activity (LDA) at three months, identifying predictive factors, and evaluating the reduction in the use of corticosteroids. Methods: A prospective real-world observational study included patients over 18 years of age with RA (ACR/EULAR 2010 criteria) who initiated CTZ and were followed for three months. Demographic, clinical, comorbidity, treatment, and disease activity data were recorded. Results: Out of 2092 RA patients treated with CTZ between 2016 and 2021, 90% had a poor prognosis, and 60% had high disease activity. Among 1673 patients followed for three months, a reduction in DAS 28 (-1.9) and HAQ (-0.63) was observed. At three months, 10.5% achieved remission, and 40% achieved LDA. Predictive factors for remission included age (OR: 0.97) and DAS 28 (OR: 0.58); for LDA, age (OR: 0.97), DAS 28 (OR: 0.61), first-line CTZ (OR: 1.6), and HAQ (OR: 0.61). Additionally, there was a reduction in the use of glucocorticoids (-3.1 mg prednisone). Conclusions: CTZ is effective in RA, emphasizing patient selection and an early treatment approach. This study supports the efficacy of CTZ.
简介赛妥珠单抗匹格（Certolizumab pegol，CTZ）是一种肿瘤坏死因子α（TNF-α）抑制剂生物制剂，在控制类风湿性关节炎（RA）方面疗效显著。确定治疗成功的预测因素并在实际临床环境中评估其疗效对决策至关重要。目的评估真实世界队列中的 RA 患者对 CTZ 的反应，测量三个月后 DAS 28、HAQ、缓解频率和低疾病活动性（LDA）的降低情况，确定预测因素，并评估皮质类固醇使用的减少情况。研究方法一项前瞻性真实世界观察研究纳入了18岁以上的RA患者（ACR/EULAR 2010标准），这些患者开始接受CTZ治疗并随访三个月。研究人员记录了患者的人口统计学、临床、合并症、治疗和疾病活动数据。结果在2016年至2021年期间接受CTZ治疗的2092名RA患者中，90%预后不良，60%疾病活动度高。在随访三个月的1673名患者中，观察到DAS 28（-1.9）和HAQ（-0.63）有所下降。三个月后，10.5% 的患者病情得到缓解，40% 的患者达到 LDA。缓解的预测因素包括年龄（OR：0.97）和 DAS 28（OR：0.58）；LDA 的预测因素包括年龄（OR：0.97）、DAS 28（OR：0.61）、一线 CTZ（OR：1.6）和 HAQ（OR：0.61）。此外，糖皮质激素的使用也有所减少（-3.1 毫克泼尼松）。结论：CTZ对RA有效，强调患者选择和早期治疗方法。本研究支持 CTZ 的疗效。
{"title":"Certolizumab pegol in severe rheumatoid arthritis: Real-world evidence in an Argentine cohort: Achievement of targets (T2T) at 3 months and predictive factors.","authors":"R. G. García Salinas, S. Magri, Álvaro Ruta","doi":"10.46856/grp.10.et182","DOIUrl":"https://doi.org/10.46856/grp.10.et182","url":null,"abstract":"Introduction: Certolizumab pegol (CTZ) is a tumor necrosis factor-alpha (TNF-α) inhibitor biological agent that has demonstrated efficacy in controlling rheumatoid arthritis (RA). Identifying predictive factors for treatment success and assessing its effectiveness in a real-world clinical setting are crucial for decision-making. Objective: To evaluate the response to CTZ in patients with RA in a real-world cohort, measuring the reduction in DAS 28, HAQ, frequency of remission, and low disease activity (LDA) at three months, identifying predictive factors, and evaluating the reduction in the use of corticosteroids. Methods: A prospective real-world observational study included patients over 18 years of age with RA (ACR/EULAR 2010 criteria) who initiated CTZ and were followed for three months. Demographic, clinical, comorbidity, treatment, and disease activity data were recorded. Results: Out of 2092 RA patients treated with CTZ between 2016 and 2021, 90% had a poor prognosis, and 60% had high disease activity. Among 1673 patients followed for three months, a reduction in DAS 28 (-1.9) and HAQ (-0.63) was observed. At three months, 10.5% achieved remission, and 40% achieved LDA. Predictive factors for remission included age (OR: 0.97) and DAS 28 (OR: 0.58); for LDA, age (OR: 0.97), DAS 28 (OR: 0.61), first-line CTZ (OR: 1.6), and HAQ (OR: 0.61). Additionally, there was a reduction in the use of glucocorticoids (-3.1 mg prednisone). Conclusions: CTZ is effective in RA, emphasizing patient selection and an early treatment approach. This study supports the efficacy of CTZ.","PeriodicalId":187344,"journal":{"name":"Global Rheumatology","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140439324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：